Noubar Afeyan's Net Worth

$7.77 Billion

Who is Noubar Afeyan?

Noubar Afeyan has an estimated net worth of $7.77 Billion. This is based on reported shares across multiple companies, which include Sana Biotechnology, Inc., Moderna, Inc., Kaleido Biosciences, Inc., TETRAPHASE PHARMACEUTICALS INC, AGIOS PHARMACEUTICALS INC, BG Medicine, Inc., BIND Therapeutics, Inc, Receptos, Inc., Omega Therapeutics, Inc., Seres Therapeutics, Inc., Editas Medicine, Inc., TransMedics Group, Inc., Quanterix Corp, Foghorn Therapeutics Inc., Denali Therapeutics Inc., CONCERT PHARMACEUTICALS, INC., SELECTA BIOSCIENCES INC, Rubius Therapeutics, Inc., Syros Pharmaceuticals, Inc., Eleven Biotherapeutics, Inc., ANTIGENICS INC /DE/, Codiak BioSciences, Inc., T2 Biosystems, Inc., Axcella Health Inc., Sigilon Therapeutics, Inc., Evelo Biosciences, Inc., HELICOS BIOSCIENCES CORP, and ACCELERON PHARMA INC.

SEC CIK

Noubar Afeyan's CIK is 0001222012

Past Insider Trading and Trends

2019 was Noubar Afeyan's most active year for acquiring shares with 37 total transactions. Noubar Afeyan's most active month to acquire stocks was the month of January. 2023 was Noubar Afeyan's most active year for disposing of shares, totalling 112 transactions. Noubar Afeyan's most active month to dispose stocks was the month of April. 2022 saw Noubar Afeyan paying a total of $96,624,828.60 for 54,754,535 shares, this is the most they've acquired in one year. In 2021 Noubar Afeyan cashed out on 129,933,660 shares for a total of $1,442,141,068.73, their largest year based on trade value.